Newsfeeds Archive - Spark Newswire

2 minute read

Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck’s Pneumococcal Shots – Analyst Says

April 10, 2:42 PM

The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the US discussing vaccination age reduction. Prevnar20 dominates with 97% market share in adults, but Vaxcyte's advanced conjugate capabilities present a competitive advantage.

MRK

1 minute read

“Top Pick for 2024”: Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales

By Nabaparna Bhattacharya

January 5, 2:52 PM

Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT),

PCVX

6 minute read

Vaxcyte Provides Clinical And Regulatory Progress Update On Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise

By Benzinga Newsdesk

January 4, 5:08 PM

-- Company Doses First Participants in Phase 2 Portion of Ongoing VAX-31 Phase 1/2 Study in Adults Following Independent Review of Phase 1 Safety and Tolerability Data; Topline Safety, Tolerability and

PCVX

1 minute read

Vaccine Player Vaxcyte Can Potentially Disrupt Pfizer’s 20-Plus-Year Near Monopoly, Says Analyst

By Vandana Singh

December 7, 4:27 PM

Mizuho Securities initiated coverage on Vaxcyte Inc (NASDAQ: PCVX), a vaccine company targeting bacterial infectious diseases (primarily for disease prevention).

PCVX

5 minute read

VAX-24 Phase 1/2 Adult Proof-Of-Concept Data Published In The Lancet Infectious Diseases Highlight Best-In-Class Potential Of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine Candidate

By Benzinga Newsdesk

December 4, 7:43 PM

-- In the Study, VAX-24 Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) at all Doses Studied -- -- All 24 Serotypes of VAX-24 at Conventional 2.2 mcg PCV Dose Met or

PCVX

2 minute read

Vaxcyte Exercises Option And Enters Into Manufacturing Rights Agreement With Sutro Biopharma To Obtain Control Over Manufacturing And Development Of Cell-Free Extract For Its Vaccine Candidates

By Benzinga Newsdesk

November 27, 5:01 PM

-- Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company's Pneumococcal Conjugate Vaccine (PCV) Franchise -- -- Manufacturing Rights Agreement

PCVX

4 minute read

Vaxcyte Doses First Participants In Phase 1/2 Clinical Study Evaluating VAX-31 For The Prevention Of Invasive Pneumococcal Disease In Adults

By Benzinga Newsdesk

November 9, 9:32 AM

-- VAX-31, a 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, is the Broadest-Spectrum PCV to Enter the Clinic -- -- Topline Safety, Tolerability and Immunogenicity Data Expected in Second Half of 2024 ----

PCVX

3 minute read

Global
News

Vaxcyte And Lonza Expand Collaboration For Global Commercial Manufacturing Of Broad-Spectrum Pneumococcal Conjugate Vaccines

By Benzinga Newsdesk

October 16, 8:32 AM

-- New Agreement to Establish Global Commercial Manufacturing Capacity for Vaxcyte's PCV Candidates, VAX-24 and VAX-31, in Adult and Pediatric Populations -- -- Expanded Collaboration Builds on Vaxcyte's Current

PCVX

5 minute read

Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names

By Ryan Glosier

April 20, 8:07 AM

Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is upon us, yet the S&P 500 has been largely stagnant in recent trading sessions.

CRSP

1 minute read

Vaxcyte Raises $500M Via Secondary Stock Offering Of 11.2M Shares At $41 Per Share

By Benzinga Newsdesk

April 19, 3:21 AM

Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten

PCVX